XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Income Statement [Abstract]        
Revenues $ 821.5 $ 770.4 $ 2,423.7 $ 2,249.9
Operating expenses:        
Salaries and benefits 242.8 228.4 716.6 666.8
Supplies 208.9 201.4 639.7 589.9
Professional and medical fees 104.0 91.0 301.4 266.0
Lease expense 21.5 23.9 65.2 67.5
Other operating expenses 49.0 48.2 148.0 147.7
Cost of revenues 626.2 592.9 1,870.9 1,737.9
General and administrative expenses 22.4 29.2 94.5 102.7
Depreciation and amortization 39.5 50.2 116.1 118.7
Transaction and integration costs 12.6 29.4 55.4 66.1
Net loss on disposals, consolidations and deconsolidations 15.6 14.7 19.0 21.5
Equity in earnings of unconsolidated affiliates (5.2) (5.2) (16.3) (12.3)
Litigation settlements 5.1 0.5 7.3 (0.8)
Loss on debt extinguishment 1.3 0.0 1.3 5.1
Other income, net (1.7) (2.2) (3.8) (10.7)
Total operating expenses 715.8 709.5 2,144.4 2,028.2
Operating income 105.7 60.9 279.3 221.7
Interest expense, net (74.9) (50.0) (205.0) (148.8)
Income before income taxes 30.8 10.9 74.3 72.9
Income tax expense (5.5) (4.5) (4.4) (13.8)
Net income 25.3 6.4 69.9 59.1
Less: Net income attributable to non-controlling interests (48.0) (38.1) (132.8) (118.7)
Net loss attributable to Surgery Partners, Inc. $ (22.7) $ (31.7) $ (62.9) $ (59.6)
Net loss per share attributable to common stockholders:        
Basic (in USD per share) $ (0.18) $ (0.25) $ (0.50) $ (0.47)
Diluted (in USD per share) [1] $ (0.18) $ (0.25) $ (0.50) $ (0.47)
Weighted average common shares outstanding:        
Basic (shares) 127,206 126,172 126,932 126,093
Diluted (shares) [1] 127,206 126,172 126,932 126,093
[1] The impact of potentially dilutive securities for all periods was not considered because the effect would be anti-dilutive.